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We read with great interest the paper by Wen et al. [1], prospec-
tively evaluating hepatitis B viral load as a signiﬁcant factor for
immunoprophylaxis failure of infants born of hepatitis B surface
antigen (HBsAg) positive mothers. The authors suggested that the
risk of immunoprophylaxis failure increased with increasing viral
load and that intervention, such as anti-viral therapy in mothers
with high viral load, may be considered. We agreed with the
authors that high maternal viral load correlated with an
increased risk of vertical transmission, but the optimal cut-off
was yet to be determined [2]. However, we believed that further
clariﬁcation of the data would be needed before change in clinical
practice can be recommended.
First of all, the timing of blood test on the viral load of the sub-
jects was not clearly stated. The authors mentioned that it was
checked in the third trimester or within 2 months after delivery.
However, the viral load may vary throughout pregnancy and after
delivery. In a retrospective study which evaluated the change of
viral load in 33 HBsAg positive mothers, of whom 9 were hepati-
tis B e antigen (HBeAg) positive, it was found that viral load
increased by a mean of 0.4 log in late pregnancy or early postpar-
tum, of which four HBeAg negative mothers had >1 log change
during pregnancy [3]. In another retrospective study, ter Borg
et al. studied 38 HBsAg pregnancies of which 24 were HBeAg
positive. Lamivudine was started in the third trimester to reduce
the viral load in 13 pregnancies. The median viral load increased
from 7.8 log10 copies/ml before, to 8.2 log10 copies/ml during
pregnancy, and then decreased to 6.8 log10 copies/ml after deliv-
ery [4]. We were not told the reason why a proportion of the
women’s blood tests were collected after delivery for viral load
testing and not before delivery, in this prospective study. Assum-
ing the postpartum viral load to be similar to the antenatal level
may give rise to a wrong conclusion. Therefore, it would be
important for the authors to provide the median gestational
weeks when the blood test was taken, and to clarify the propor-
tion of mothers having postpartum test. Furthermore, as the
authors also pointed out, the result would be more meaningful
if the viral load levels were obtained before 28 weeks of gesta-
tion. Anti-viral therapy was started from 28 weeks of gestation
in most of the trials evaluating the efﬁcacy of anti-viral treatment
to decrease the risk of immunoprophylaxis failure in women with
high viral load [5]. Viral load quantiﬁcation in the late third tri-
mester, at delivery, or even after delivery, would be less useful
clinically as intervention to alter outcome may not be possible.
Caesarean delivery could not decrease the risk of immunopro-
phylaxis failure [2] and late viral load quantiﬁcation would not
allow adequate time for anti-viral treatment to decrease viralJournal of Hepatology 20Secondly, we also wondered if any subjects were receiving
anti-viral therapy during the studied period. Anti-viral therapy
initiated after the blood test before delivery, or vice versa, could
affect the viral load level and subsequent correlation with risk
of the immunoprophylaxis failure. Thirdly, horizontal transmis-
sion of hepatitis B virus was possible [6] in 17.5% of children
who were tested for HBsAg at 1–3 years of age. The HBsAg posi-
tive status in this group could be due to horizontal infection
rather than genuine immunoprophylaxis failure. Finally, we were
interested in the high rate of invasive prenatal diagnostic test
(amniocentesis/CVS) and ﬁrst vaccine given beyond 24 hours in
the ten infants who suffered from chronic hepatitis B infection.
Could these be the potential factors that led to a higher rate of
immunoprophylaxis failure? We hope the authors could provide
more data on that.E-mail address: kelvincheung82@hotmail.com
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